Department of Anesthesiology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.
Department of Anesthesiology, Xinchang County People's Hospital, Xinchang, Zhejiang Province, People's Republic of China.
Drug Des Devel Ther. 2023 May 4;17:1347-1356. doi: 10.2147/DDDT.S408076. eCollection 2023.
Patients with obesity are more susceptible to hypoxemia. Anesthetic management for patients with obesity undergoing painless gastroscopy presents a severe challenge for anesthesiologists. Esketamine is a NMDA antagonist that has been proven to be beneficial for ameliorating respiratory depression owing to its sympathomimetic effect; however, there are no relevant reports on its use in patients with obesity. We designed a randomized controlled trial to evaluate whether esketamine can be the ideal adjuvant to propofol sedation in patients with obesity undergoing painless gastroscopy.
A total of 104 patients with obesity undergoing painless gastroscopy were randomly divided into group C (propofol+saline) and group S (propofol+esketamine 0.25 mg/kg). Anesthesia was induced by 2 mg/kg propofol with saline or esketamine. The consumption of propofol, hemodynamic parameters, duration of procedure, induction time, postoperative awakening time, and orientation recovery time were recorded. Adverse events and satisfaction scores were also recorded.
Propofol consumption was 274.4±22.6 mg and 201.3±16.6 mg in groups C and S, respectively. The induction time of groups C and S were 25.4±2.3 s and 17.8±1.9 s, respectively. The postoperative awakening times of groups C and S were 6.2±1.1 min and 4.8±1.3 min, respectively. Hemodynamic parameters were more stable in group S than in group C. The incidence of adverse events such as injection pain, hypoxemia, hypotension, bradycardia, choking, and body movement were significantly lower in group S. The satisfaction scores of the endoscopist and anesthesiologist were (4.58±0.49 vs 3.71±0.83) and (4.75±0.44 vs 3.33±0.92), respectively.
The combination of propofol and esketamine (0.25 mg/kg) improves the safety and reduces the incidence of adverse events in patients with obesity during painless gastroscopy. Thus, this method is worthy of clinical application.
ChiCTR 2200062547.
肥胖患者更容易发生低氧血症。对于接受无痛胃镜检查的肥胖患者,麻醉管理对麻醉师来说是一个严峻的挑战。氯胺酮是一种 NMDA 拮抗剂,由于其拟交感作用,已被证明对改善呼吸抑制有益;然而,目前尚无关于其在肥胖患者中应用的相关报道。我们设计了一项随机对照试验,以评估氯胺酮是否可以成为肥胖患者行无痛胃镜检查时异丙酚镇静的理想辅助药物。
共纳入 104 例肥胖患者行无痛胃镜检查,随机分为 C 组(异丙酚+生理盐水)和 S 组(异丙酚+氯胺酮 0.25mg/kg)。两组患者均采用 2mg/kg 异丙酚诱导麻醉,其中 C 组给予生理盐水,S 组给予氯胺酮 0.25mg/kg。记录两组患者的异丙酚用量、血流动力学参数、操作时间、诱导时间、术后苏醒时间、定向恢复时间,记录不良反应和满意度评分。
C 组和 S 组的异丙酚用量分别为 274.4±22.6mg 和 201.3±16.6mg。C 组和 S 组的诱导时间分别为 25.4±2.3s 和 17.8±1.9s。C 组和 S 组的术后苏醒时间分别为 6.2±1.1min 和 4.8±1.3min。S 组的血流动力学参数较 C 组更为稳定。S 组注射痛、低氧血症、低血压、心动过缓、呛咳和躯体运动等不良反应的发生率明显低于 C 组。内镜医师和麻醉医师的满意度评分分别为(4.58±0.49)分和(4.75±0.44)分。
异丙酚与氯胺酮(0.25mg/kg)联合应用可提高肥胖患者无痛胃镜检查的安全性,降低不良反应发生率,值得临床推广应用。
ChiCTR2200062547。